Vγ9Vδ2 T-cells are potent inhibitors of SARS-CoV-2 replication and represent effector phenotypes in COVID-19 patients.

Anti-viral immunity BTN3A Immunotherapy SARS-CoV-2 Vγ9Vδ2 T cells

Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
01 Apr 2024
Historique:
received: 18 10 2023
revised: 11 03 2024
accepted: 28 03 2024
medline: 1 4 2024
pubmed: 1 4 2024
entrez: 1 4 2024
Statut: aheadofprint

Résumé

Vγ9Vδ2 T-cells play a key role in the innate immune response to viral infections through butyrophilin (BTN)-3A. Here, we reported that blood Vγ9Vδ2 T-cells decreased in clinically mild COVID-19 compared to healthy volunteers (HV), and was maintained up to 28-days and in the recovery period. Terminally differentiated Vγ9Vδ2 T-cells tend to be enriched on the day of diagnosis, 28-days after and during the recovery period. These cells showed cytotoxic and inflammatory activities following anti-BTN3A activation. BTN3A upregulation and Vγ9Vδ2 T-cell infiltration were observed in a lung biopsy from a fatal SARS-CoV-2 infection. In vitro, SARS-CoV-2 infection increased BTN3A expression in macrophages and lung cells that enhanced the anti-SARS-CoV-2 Vγ9Vδ2 T-cells cytotoxicity and IFNγ and TNFα. Increasing concentrations of anti-BTN3A lead to viral replication inhibition. Altogether, we report that Vγ9Vδ2 T-cells are important in the immune response against SARS-CoV-2 infection and that activation by an anti-BTN3A antibody may enhance their response.

Identifiants

pubmed: 38557809
pii: 7638459
doi: 10.1093/infdis/jiae169
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Laetitia Gay (L)

Aix-Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
ImCheck Therapeutics, Marseille, France.

Marie-Sarah Rouviere (MS)

CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli Calmettes, Marseille, France.

Soraya Mezouar (S)

Aix-Marseille University, Etablissement français du sang, Centre national de la recherche scientifique, Anthropologie bio-culturelle, droit, éthique et santé, "Biologie des Groupes Sanguins", Marseille, France.

Manon Richaud (M)

CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli Calmettes, Marseille, France.

Laurent Gorvel (L)

CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli Calmettes, Marseille, France.

Etienne Foucher (E)

ImCheck Therapeutics, Marseille, France.

Bernard La Scola (B)

Aix-Marseille Univ, IRD, APHM, MEPHI, Marseille, France.

Amélie Menard (A)

Aix-Marseille University, Etablissement français du sang, Centre national de la recherche scientifique, Anthropologie bio-culturelle, droit, éthique et santé, "Biologie des Groupes Sanguins", Marseille, France.

Jérôme Allardet-Servent (J)

Unité COVID-Long, service de médecine interne CHU NORD, APHM Marseille, France.
Service de Réanimation, Hôpital Européen Marseille, France.

Philippe Halfon (P)

Département de Médecine Interne et Maladies Infectieuses, Hôpital Européen-Laboratoire Alphabio-Biogroup, Marseille, France.

Paul Frohna (P)

ImCheck Therapeutics, Marseille, France.

Carla Cano (C)

ImCheck Therapeutics, Marseille, France.

Jean-Louis Mege (JL)

Aix-Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Aix-Marseille Univ, APHM, Hôpital de la Conception, Laboratoire d'Immunologie, Marseille, France.

Daniel Olive (D)

CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli Calmettes, Marseille, France.

Classifications MeSH